Total Funding
48
72
Total FundingSeries A raised
Growth Score 48 in past quarter
-31 pts
Heat Score 72 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
43250
ARTIDIS is committed to innovation and excellence in order to bring the future of health care to people.
- Tobias Appenzeller: Head, Clinical Operations & QMS, Co-Founder
- Marija Plodinec: CEO & Co-Founder
About the Company
ARTIDIS's nanomechanical sensor captures the physical properties of tissue enabling the clinician to differentiate between benign and malignant tissue in under three hours. In addition, the technology allows the clinician to define the aggressiveness of the tumor with very high accuracy based on the nanomechanical signature of the cells. Only
very soft cells can squeeze through all different tissues to create distant metastases that are responsible for more than 90% of cancer related deaths. The nano-probe measures the tissue’s physical properties allowing us to discover robust nano-mechanical biomarkers and predict disease development. Moreover, ARTIDIS technology is not limited to cancer and can analyze any living tissue.